Skip to Content

    Genetic testing is having a heyday as the process of sequencing genomes becomes cheaper and more ubiquitous. Illumina has capitalized with its testing expertise. It partners with consumer-focused DNA testing services like 23andMe, and with pharma giants like Bristol-Myers Squibb who seek its help with drug development. Last year, the FDA approved Illumina’s companion diagnostic for Amgen’s Vectibix, a drug for metastatic colorectal cancer. In the past 12 months, Illumina has provided a 60% return to shareholders; over the past five years, that figure is 306%.

    Fortune Data StoreLooking for leads, investment insights, or competitive intelligence?Get Premium Access

    Company Information

    Overall Score2.7
    Sector
    Health Care
    Industry
    Life Sciences Tools and Services
    CEO
    Francis A. deSouza
    Websitehttp://www.illumina.com
    Employees6,200
    HQ Location
    San Diego
    Revenues ($M) (Past 12 Months)$3,104
    Profits ($M) (Past 12 Months)$648
    Market Value as of Oct. 10, 2018 ($M)$44,800